AMSTAR 2

AMSTAR 2
  • 文章类型: Journal Article
    进行高质量的评论概述(OoR)非常耗时。因为系统评价(SRs)的质量各不相同,在进行OoR时,有必要批判性地评估SR。一个完善的评估工具是评估系统审查的测量工具(AMSTAR)2,每次申请大约需要15-32分钟。为了节省时间,我们开发了两个快速节俭的决策树(FFT),用于在全文筛选阶段(筛选FFT)或最终的SR库(快速评估FFT)评估OoR的SR的方法学质量。要构建用于开发FFT的数据集,我们确定了已发表的AMSTAR2评估。AMSTAR2的总体置信度等级被用作标准,16个项目被用作线索。从24种出版物中获得了一千五百十九种评估,并分为培训和测试数据集。产生的筛选FFT由三个项目组成,并正确识别所有非临界低质量SR(灵敏度为100%),但有59%的阳性预测值。三项快速评估FFT正确识别80%的高质量SR,正确识别97%的低质量SR,导致95%的准确度。FFT需要16个AMSTAR2项目中的约10%。可以在全文筛选期间应用筛选FFT以排除具有严重低质量的SR。快速评估FFT可以应用于最终SR池以识别可能具有高方法质量的SR。
    Conducting high-quality overviews of reviews (OoR) is time-consuming. Because the quality of systematic reviews (SRs) varies, it is necessary to critically appraise SRs when conducting an OoR. A well-established appraisal tool is A Measurement Tool to Assess Systematic Reviews (AMSTAR) 2, which takes about 15-32 min per application. To save time, we developed two fast-and-frugal decision trees (FFTs) for assessing the methodological quality of SR for OoR either during the full-text screening stage (Screening FFT) or to the resulting pool of SRs (Rapid Appraisal FFT). To build a data set for developing the FFT, we identified published AMSTAR 2 appraisals. Overall confidence ratings of the AMSTAR 2 were used as a criterion and the 16 items as cues. One thousand five hundred and nineteen appraisals were obtained from 24 publications and divided into training and test data sets. The resulting Screening FFT consists of three items and correctly identifies all non-critically low-quality SRs (sensitivity of 100%), but has a positive predictive value of 59%. The three-item Rapid Appraisal FFT correctly identifies 80% of the high-quality SRs and correctly identifies 97% of the low-quality SRs, resulting in an accuracy of 95%. The FFTs require about 10% of the 16 AMSTAR 2 items. The Screening FFT may be applied during full-text screening to exclude SRs with critically low quality. The Rapid Appraisal FFT may be applied to the final SR pool to identify SR that might be of high methodological quality.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    本综述的目的是基于当前的系统评价和荟萃分析,调查环境空气污染与肥胖之间关联的综合和综合证据。来自包括PubMed在内的数据库的相关研究,EMBASE,WebofScience,还有Cochrane图书馆,在分析中考虑了2023年7月16日之前发布的。所有选定的系统评价和荟萃分析均按照PRISMA指南纳入。使用AMSTAR2工具评估偏倚风险和方法学质量。该总括审查的方案记录在PROSPERO中,注册号为:CRD42023450191。这项综述确定了7项研究,包括5个荟萃分析和2个系统综述,评估空气污染物对肥胖的影响。通常检查的空气污染物包括PM1,PM2.5,PM10,NO2,SO2,O3。大多数纳入的研究表明,空气污染暴露与肥胖风险增加呈正相关。空气污染对肥胖的影响因不同的环境空气污染物而异。这项研究提供了令人信服的证据,表明暴露于空气污染与肥胖风险呈正相关。这些发现进一步表明了加强大气污染防治的重要性。未来的研究应该阐明将空气污染与肥胖联系起来的可能机制和途径。
    The objective of this umbrella review was to investigate comprehensive and synthesized evidence of the association between ambient air pollution and obesity based on the current systematic reviews and meta-analyses. Related studies from databases including PubMed, EMBASE, Web of Science, and the Cochrane Library, published before July 16, 2023, were considered in the analysis. All selected systematic reviews and meta-analyses were included in accordance with PRISMA guidelines. The risk of bias and the methodological quality were evaluated using the AMSTAR 2 tool. The protocol for this umbrella review was documented in PROSPERO with the registration number: CRD42023450191. This umbrella review identified 7 studies, including 5 meta-analyses and 2 systematic reviews, to assess the impacts of air pollutants on obesity. Commonly examined air pollutants included PM1, PM2.5, PM10, NO2, SO2, O3. Most of the included studies presented that air pollution exposure was positively associated with the increased risk of obesity. The impact of air pollution on obesity varied by different ambient air pollutants. This study provided compelling evidence that exposure to air pollution had a positive association with the risk of obesity. These findings further indicate the importance of strengthening air pollution prevention and control. Future studies should elucidate the possible mechanisms and pathways linking air pollution to obesity.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:从现有的系统评价和荟萃分析中,使用3D和/或结合2D和3D方法评估当前关于清晰对齐和根吸收的证据,并使用AMSTAR2工具确定根吸收和清晰对齐之间的关系。方法:全面的文献检索系统评价调查对齐和根吸收,发布至2022年12月31日,进行了。搜索了以下电子数据库:MEDLINE通过PubMed,EMBASE,谷歌学者,科学直接,WebofScience,Scopus,LIVIVIVO,和LILACS。没有语言限制。纳入标准仅限于仅利用3D方法或结合2D和3D技术进行的针对根吸收的研究。使用“评估系统评价的测量工具(AMSTAR2)”工具筛选和分析数据的质量。数据提取由两名作者独立进行。根据评论中阐明的主要发现,对收集的信息进行了分类和叙述。结果:在最初确定的总共1221项潜在合格研究中,在排除不相关研究后,4篇系统综述符合纳入标准。其中,两项系统评价(50%)被归类为低质量,而其余两个(50%)被认为是严重低质量。结论:基于四个系统评价的结果,使用透明对齐器的牙根吸收率低于使用固定对齐器的牙根吸收率.建议谨慎对待这一结论的解释,因为现有证据的质量被评估为非常低。需要更高质量的系统评价来证实这一结论。
    Background: To evaluate the current evidence on clear aligners and root resorption using 3D and/or combined 2D and 3D methods from available systematic reviews and meta-analyses and to determine the relationship between root resorption and clear aligners using the AMSTAR 2 tool. Methods: A comprehensive literature search of systematic reviews investigating aligners and root resorption, published up until 31 December 2022, was conducted. The following electronic databases were searched: MEDLINE via PubMed, EMBASE, Google Scholar, Science Direct, Web of Science, Scopus, LIVIVO, and LILACS. There were no language restrictions. The inclusion criteria were restricted to studies focusing on root resorption utilizing either 3D methods exclusively or a combination of 2D and 3D techniques. Data were screened and analyzed for quality using the \"A Measurement Tool to Assess Systematic Reviews (AMSTAR 2)\" tool. Data extraction was conducted independently by two authors. The gathered information was categorized and synthesized narratively based on the primary findings elucidated within the reviews. Results: Out of a total of 1221 potentially eligible studies initially identified, 4 systematic reviews met the inclusion criteria following the exclusion of irrelevant studies. Among these, two systematic reviews (50%) were classified as low-quality, while the remaining two (50%) were deemed to be of critically low quality. Conclusions: Based on the findings of four systematic reviews, the root resorption rate was lower with the use of clear aligners than with fixed aligners. It is advisable to approach the interpretation of this conclusion with caution, as the quality of the available evidence is assessed to be very low. Higher quality systematic reviews are needed to substantiate this conclusion.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    系统评价(SRs)在医疗保健决策实践中具有重要作用。使用质量评估工具评估对SR结果的总体信心,如“评估系统评论2的计量工具”(AMSTAR2),是至关重要的,因为并非所有的SR都是使用最严格的方法进行的。在这篇文章中,我们介绍一个免费的,名为\"amstar2Vis\"(https://github.com/bougioukas/amstar2Vis)的开源R包,提供易于使用的功能来呈现对SR的关键评估,基于AMSTAR2清单的项目。概述了一个说明性示例,描述创建包含项目评级和总体置信度评级的详细表格所涉及的步骤,生成一个堆叠条形图,显示每个AMSTAR2项目的评级分布为SR的百分比,并创建一个“ggplot2”图,显示总体置信度等级的分布(“极低,\"\"低,\"\"中等,\"或\"高\")。我们希望“amstar2Vis”对概述作者和方法学家有用,他们使用AMSTAR2核对表评估SR的质量,并促进相关的可发表表格和数字的制作。未来的研究和应用可以进一步研究我们软件包的功能或潜在改进。
    Systematic reviews (SRs) have an important role in the healthcare decision-making practice. Assessing the overall confidence in the results of SRs using quality assessment tools, such as \"A MeaSurement Tool to Assess Systematic Reviews 2\" (AMSTAR 2), is crucial since not all SRs are conducted using the most rigorous methods. In this article, we introduce a free, open-source R package called \"amstar2Vis\" (https://github.com/bougioukas/amstar2Vis) that provides easy-to-use functions for presenting the critical appraisal of SRs, based on the items of AMSTAR 2 checklist. An illustrative example is outlined, describing the steps involved in creating a detailed table with the item ratings and the overall confidence ratings, generating a stacked bar plot that shows the distribution of ratings as percentages of SRs for each AMSTAR 2 item, and creating a \"ggplot2\" graph that shows the distribution of overall confidence ratings (\"Critically Low,\" \"Low,\" \"Moderate,\" or \"High\"). We expect \"amstar2Vis\" to be useful for overview authors and methodologists who assess the quality of SRs with AMSTAR 2 checklist and facilitate the production of pertinent publication-ready tables and figures. Future research and applications could further investigate the functionality or potential improvements of our package.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:一些系统评价已经讨论了数字技术在慢性阻塞性肺疾病(COPD)治疗和监测中的应用。
    目的:本研究旨在评估系统评价是否考虑了性别的影响,性别,通过对此类系统评价的概述,了解数字技术治疗和监测COPD的结果。本综述的目的是(1)描述评论中使用的性别或性别的定义;(2)确定是否考虑性别,性别,或年龄是在审查中计划的;(3)确定性别,性别,或年龄在审查结果中报告;(4)确定性别,性别,或年龄纳入对临床实践的影响;(5)创建证据图,以制定基于性别的COPD个性化临床建议,性别,或年龄多样性。
    方法:MEDLINE,Cochrane图书馆,认识论,WebofScience,并检索纳入的系统评价的参考书目至2022年6月.纳入基于PICOS框架:(1)人群(COPD),(2)干预(任何数字技术),(3)比较(任何),(4)结果(任何),(5)研究类型(系统评价)。研究由2位作者根据标题和摘要以及全文筛选独立选择。数据由一位作者提取,并由另一位作者检查。数据项包括系统评价特征;PICOS标准;以及与性别相关的变量,性别,或年龄。系统评价使用评估系统评价的测量工具,版本2(AMSTAR2)。数据使用描述性统计进行综合。
    结果:在1439条记录中,本概述包括2010年至2022年发布的30篇系统综述。根据AMSTAR2,对30项审查中的25项(83%)的结果的信心极低。评论的重点是可能取决于性别的用户结果,性别,或年龄,如疗效或有效性(25/30,83%)和接受度,满意,或对COPD数字技术的依从性(3/30,10%)。评论报告了主要研究特征中的性别或性别(19/30系统评论)或年龄(25/30系统评论)。然而,30条评论中只有1条将年龄纳入亚组分析,30篇评论中有3篇确定了性的影响,性别,或年龄作为证据缺口。
    结论:本概述表明,性别的影响,性别,在30项用于COPD治疗和监测的数字技术的系统评价中,很少考虑年龄.此外,系统评价没有纳入性别,性别,也没有年龄对临床实践的影响。我们建议未来的系统评价应该(1)评估性的影响,性别,或年龄对数字技术治疗和监测COPD结果的影响;(2)更好地遵守报告指南,以提高对审查结果的信心.
    背景:PROSPEROCRD42022322924;https://www.crd.约克。AC.uk/prospro/display_record.php?RecordID=322924。
    RR2-10.2196/40538。
    Several systematic reviews have addressed digital technology use for treatment and monitoring of chronic obstructive pulmonary disease (COPD).
    This study aimed to assess if systematic reviews considered the effects of sex, gender, or age on the outcomes of digital technologies for treatment and monitoring of COPD through an overview of such systematic reviews. The objectives of this overview were to (1) describe the definitions of sex or gender used in reviews; (2) determine whether the consideration of sex, gender, or age was planned in reviews; (3) determine whether sex, gender, or age was reported in review results; (4) determine whether sex, gender, or age was incorporated in implications for clinical practice in reviews; and (5) create an evidence map for development of individualized clinical recommendations for COPD based on sex, gender, or age diversity.
    MEDLINE, the Cochrane Library, Epistemonikos, Web of Science, and the bibliographies of the included systematic reviews were searched to June 2022. Inclusion was based on the PICOS framework: (1) population (COPD), (2) intervention (any digital technology), (3) comparison (any), (4) outcome (any), and (5) study type (systematic review). Studies were independently selected by 2 authors based on title and abstract and full-text screening. Data were extracted by 1 author and checked by another author. Data items included systematic review characteristics; PICOS criteria; and variables related to sex, gender, or age. Systematic reviews were appraised using A Measurement Tool to Assess Systematic Reviews, version 2 (AMSTAR 2). Data were synthesized using descriptive statistics.
    Of 1439 records, 30 systematic reviews published between 2010 and 2022 were included in this overview. The confidence in the results of 25 of the 30 (83%) reviews was critically low according to AMSTAR 2. The reviews focused on user outcomes that potentially depend on sex, gender, or age, such as efficacy or effectiveness (25/30, 83%) and acceptance, satisfaction, or adherence (3/30, 10%) to digital technologies for COPD. Reviews reported sex or gender (19/30 systematic reviews) or age (25/30 systematic reviews) among primary study characteristics. However, only 1 of 30 reviews included age in a subgroup analysis, and 3 of 30 reviews identified the effects of sex, gender, or age as evidence gaps.
    This overview shows that the effects of sex, gender, or age were rarely considered in 30 systematic reviews of digital technologies for COPD treatment and monitoring. Furthermore, systematic reviews did not incorporate sex, gender, nor age in their implications for clinical practice. We recommend that future systematic reviews should (1) evaluate the effects of sex, gender, or age on the outcomes of digital technologies for treatment and monitoring of COPD and (2) better adhere to reporting guidelines to improve the confidence in review results.
    PROSPERO CRD42022322924; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=322924.
    RR2-10.2196/40538.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:评估糖尿病足溃疡(DFU)脱细胞真皮基质(ADM)的系统评价(SRs)/Meta分析(MAs)的方法学质量和结果指标的可靠性。方法:我们从PubMed中检索并检索了关于ADM在DFU中的应用的SR和MA,WebofScience,科克伦图书馆,EMBASE,CNKI,CBM,万方,VIP数据库。我们采用AMSTAR2来评估方法学质量,建议的分级,评估,开发和评估(等级)系统评分,以及包括SRs/MA的证据强度。我们排除了重叠的随机对照试验(RCT),并对主要RCT进行了重新MA。结果:共纳入7个SRs/MA。AMSTAR2评估结果显示总体质量较低;GRADE系统显示证据质量中等到非常低。我们的re-MA显示ADM优于护理标准(SOC),关于12周时完全伤口愈合率(RR=1.74,95%CI:1.34-2.25,P<0.0001),16周时伤口完全愈合率(RR=1.50,95%CI:1.26-1.77,P<.00001);愈合时间(MD=-2.06,95%CI:-2.57至-1.54,P<.00001)和不良事件(RR=0.62,95%CI:0.49-0.80,P=.0002)。然而,在溃疡面积减少和生活质量的结局指标方面,ADM组和SOC组之间尚未达成共识;亚组分析显示,12周时,异种移植ADM组和SOC组之间无统计学显著差异(RR=1.36,95%CI:0.95~1.93,P=.09).结论:目前的证据表明,ADM在治疗DFU方面比标准护理更有效,特别是对于全厚度,未感染,和非缺血性足部溃疡,但证据质量低.因此,这一概述的结果应该辩证和谨慎地解释,ADM在DFU中的作用有待进一步探索。
    Aims: To evaluate the reliability of the methodological quality and outcome measures of systematic reviews (SRs)/metaanalyses (MAs) of the acellular dermal matrix (ADM) for diabetic foot ulcer (DFU). Methods: We searched and retrieved SRs and MAs on the application of ADM for DFU from PubMed, Web of Science, The Cochrane Library, EMBASE, CNKI, CBM, WanFang, and VIP databases. We employed AMSTAR 2 to assess methodological quality, Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system to grade, and the strength of evidence of included SRs/MAs. We excluded the overlapping randomized controlled trials (RCTs) and conducted a re-MA of the primary RCTs. Results: A total of 7 SRs/MAs were included. Results from the AMSTAR 2 evaluation revealed a low overall quality; the GRADE system showed that the evidence was of moderate to very low quality. Our re-MA showed that ADM was superior to standard of care (SOC), with regards to complete wound healing rate at 12 weeks (RR = 1.74, 95% CI:1.34-2.25, P < .0001), complete wound healing rate at 16 weeks (RR = 1.50, 95% CI: 1.26-1.77, P < .00001); healing time (MD = -2.06, 95% CI: -2.57 to -1.54, P < .00001) and adverse events (RR = 0.62, 95% CI: 0.49-0.80, P = .0002). However, a consensus has not yet been reached between ADM and SOC groups with regard to outcome indicators of the reduction of ulcer area and quality of life; and subgroup analyses showed no statistically significant differences between the xenograft ADM and SOC groups (RR = 1.36, 95% CI: 0.95-1.93, P = .09) at 12 weeks. Conclusion: Current evidence suggests that ADM is more effective than the standard of care in the treatment of DFU, particularly for full-thickness, noninfected, and nonischemic foot ulcers, but with low evidence quality. Therefore, the results of this overview should be interpreted dialectically and prudently, and the role of ADM in DFU needs further exploration.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    OBJECTIVE: To evaluate the report quality, methodological quality and evidence quality of the systematic reviews and meta-analyses (SRs/MAs) of acupuncture for in vitro fertilization-embryo transfer (IVF-ET).
    METHODS: The SRs/MAs of acupuncture for IVF-ET were searched electronically from databases of CNKI, Wanfang, VIP, SinoMed, PubMed, Embase, Cochrane Library, from inception of each database to September 27th, 2022. Two reviewers independently screened the literature and extracted the data. Using PRISMA statement, the AMSTAR 2 scale and the GRADE system, the report quality, methodological quality and evidence quality of the included SRs/MAs were assessed.
    RESULTS: A total of 28 SRs/MAs were included, with PRISMA scores ranging from 8.5 points to 27 points. The problems of report quality focused on protocol and registration, retrieval, risk of bias in studies, additional analysis, limitations and funding. The methodological quality of included studies was generally low, reflecting on items 2, 3, 7, 10, 12 and 16. A total of 85 outcome indexes were included in the GRADE system for evidence grade evaluation. Most of the evidences were low or very low in quality. The reasons for the downgrade were related to study limitations, inconsistency, imprecision and publication bias.
    CONCLUSIONS: Acupuncture therapy improves the outcomes of IVF-ET, but the methodological quality and evidence quality of related SRs/MAs are low. It is recommended to conduct more high-quality studies in the future to provide more reliable evidences.
    目的: 对针灸辅助体外受精胚胎移植(IVF-ET)的系统评价(SR)/Meta分析(MA)进行报告质量、方法学质量和证据质量的再评价。方法: 计算机检索中国期刊全文数据库(CNKI)、万方数据知识服务平台(Wanfang)、维普中文期刊服务平台(VIP)、中国生物医学文献数据库(SinoMed)、PubMed、EMbase、Cochrane Library中针灸辅助IVF-ET的SR/MA。检索时限均为建库至2022年9月27日。由2名研究员独立筛选文献、提取资料后,采用PRISMA声明、AMSTAR 2量表和GRADE系统分别评价纳入SR/MA的报告质量、方法学质量和证据质量。结果: 共纳入28篇SR/MA,PRISMA评分在8.5~27分。报告质量问题主要表现在方案和注册、检索、研究偏倚、其他分析、局限性、资金支持等方面。纳入研究的方法学质量整体偏低,问题主要集中在条目2、3、7、10、12、16。共85个结局指标纳入GRADE系统进行证据等级评价,大部分证据质量为低或极低,降级的原因主要与研究的局限性、不一致性、不精确性和发表偏倚有关。结论: 针灸辅助IVF-ET治疗可以改善不孕患者的妊娠结局,但相关SR/MA的方法学质量和证据质量均较低,建议今后开展更多高质量的研究以提供更可靠的循证依据。.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:吲哚菁绿(ICG)是一种可注射的荧光染料,最近作为腹腔镜和机器人手术过程中辅助术中可视化的一种手段而受到欢迎。已经发表了许多系统评价和荟萃分析。我们进行了一项荟萃综述,以综合这些研究的结果。
    方法:搜索PubMed和Embase以确定应对ICG在腹部手术中使用的系统评价和荟萃分析,包括代谢减肥手术,胆囊切除术,结肠直肠,食道,胃,肝-胰腺-胆道,妇产科(OG),儿科手术,肿瘤外科,泌尿外科,(腹部)血管外科,肾上腺和脾手术,和跨学科任务,直到2023年9月。我们将检索到的荟萃分析提交给基于AMSTAR2仪器的定性分析。
    结果:我们确定了116项研究,41项系统评价(SRs)和75项荟萃分析(MA),跨越2013-2023年。调查最彻底的(亚)专科是结直肠(6个SRs,25MA),OG(9SR,15MA),和HPB(4个SRs,12MA)。有趣的是,关于施用的ICG剂量有很高的异质性,路线,和时间。ICG的使用在预防吻合口漏方面提供了明显的好处。尤其是在结肠直肠和食道手术后。OG后前哨淋巴结检测没有明显的好处。根据AMSTAR2工具,大多数荟萃分析的排名为“极低”(34.7%)或“低”(58.7%)质量。只有五项荟萃分析(6.7%)符合“中等”质量,而没有“高质量”的评论。
    结论:无论相关文献和综述如何丰富,外科医生在解释他们在腹部手术中使用ICG的结果时应谨慎。未来的审查应侧重于确保方法学活力;建立明确的ICG剂量方案,给药途径,和时间安排;提高报告质量。其他数据源(例如,注册表)和新的数据分析方法(例如,机器学习)也可能有助于增强ICG作为外科手术决策工具的作用。
    BACKGROUND: Indocyanine green (ICG) is an injectable fluorochrome that has recently gained popularity as a means of assisting intraoperative visualization during laparoscopic and robotic surgery. Many systematic reviews and meta-analyses have been published. We conducted a meta-review to synthesize the findings of these studies.
    METHODS: PubMed and Embase were searched to identify systematic reviews and meta-analyses coping with the uses of ICG in abdominal operations, including Metabolic Bariatric Surgery, Cholecystectomy, Colorectal, Esophageal, Gastric, Hepato-Pancreato-Biliary, Obstetrics and Gynecology (OG), Pediatric Surgery, Surgical Oncology, Urology, (abdominal) Vascular Surgery, Adrenal and Splenic Surgery, and Interdisciplinary tasks, until September 2023. We submitted the retrieved meta-analyses to qualitative analysis based on the AMSTAR 2 instrument.
    RESULTS: We identified 116 studies, 41 systematic reviews (SRs) and 75 meta-analyses (MAs), spanning 2013-2023. The most thoroughly investigated (sub)specialties were Colorectal (6 SRs, 25 MAs), OG (9 SRs, 15 MAs), and HPB (4 SRs, 12 MAs). Interestingly, there was high heterogeneity regarding the administered ICG doses, routes, and timing. The use of ICG offered a clear benefit regarding anastomotic leak prevention, particularly after colorectal and esophageal surgery. There was no clear benefit regarding sentinel node detection after OG. According to the AMSTAR 2 tool, most meta-analyses ranked as \"critically low\" (34.7%) or \"low\" (58.7%) quality. There were only five meta-analyses (6.7%) that qualified as \"moderate\" quality, whereas there were no \"high\" quality reviews.
    CONCLUSIONS: Regardless of the abundance of pertinent literature and reviews, surgeons should be cautious when interpreting their results on ICG use in abdominal surgery. Future reviews should focus on ensuring methodological vigor; establishing clear protocols of ICG dose, route of administration, and timing; and improving reporting quality. Other sources of data (e.g., registries) and novel methods of data analysis (e.g., machine learning) might also contribute to an enhanced role of ICG as a decision-making tool in surgery.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    本研究旨在评估评估系统评论的测量工具(AMSTAR)2评估在心血管领域干预措施的综述(概述)中的方法和结果,并确定与这些结果相关的因素。MEDLINE,Scopus,并在2022年11月之前搜索了Cochrane系统评论数据库。符合条件的是心血管干预措施的概述,分析随机对照试验(RCT)的系统评价(SRs)。提取的数据包括概述和SRs的特征以及AMSTAR2评估方法和结果。使用描述性统计和逻辑回归综合数据,以探索SR特征与提取的AMSTAR2总体评级之间的潜在关联(“高-中等”与\"Low-Criticallylow\").关于单个AMSTAR2项目的原始结果被输入到官方AMSTAR2在线工具中,并将重新计算的总体信心评级与概述中提供的评级进行比较。确定的所有34个概述均在2019年至2022年之间发布。根据AMSTAR2开发人员建议的算法,在74%的概述中指出了总体置信度的评级。包含的679个独特SR主要具有“极低”(53%)或“低”(18.7%)的置信度,并且在项目2中表现不佳(协议,no=65.2%)和7(排除研究列表,否=84%)。SR的以下特征与较高的总体评级显着相关:Cochrane起源,药理干预,包括独家RCT,引用方法和报告指南,协议,AMSTAR2发布后没有资金和出版物。一般来说,与官方AMSTAR2在线工具相比,概述作者倾向于偏离原始评级方案,并将更高的评级赋予SR。心血管干预措施概述中包含的大多数SR对其结果的置信度极低或低。概述作者应该更透明地了解用于得出SR总体置信度的方法。
    This study aimed to assess the methods and outcomes of The Measurement Tool to Assess systematic Reviews (AMSTAR) 2 appraisals in overviews of reviews (overviews) of interventions in the cardiovascular field and identify factors that are associated with these outcomes. MEDLINE, Scopus, and the Cochrane Database of Systematic Reviews were searched until November 2022. Eligible were overviews of cardiovascular interventions, analyzing systematic reviews (SRs) of randomized controlled trials (RCTs). Extracted data included characteristics of overviews and SRs and AMSTAR 2 appraisal methods and outcomes. Data were synthesized using descriptive statistics and logistic regression to explore potential associations between the characteristics of SRs and extracted AMSTAR 2 overall ratings (\"High-Moderate\" vs. \"Low-Critically low\"). The original results on individual AMSTAR 2 items were entered into the official AMSTAR 2 online tool and the recalculated overall confidence ratings were compared to those provided in overviews. All 34 overviews identified were published between 2019 and 2022. Rating of overall confidence following the algorithm suggested by AMSTAR 2 developers was noted in 74% of overviews. The 679 unique included SRs were mainly of \"Critically low\" (53%) or \"Low\" (18.7%) confidence and underperformed in items 2 (Protocol, no = 65.2%) and 7 (List of excluded studies, no = 84%). The following characteristics of SRs were significantly associated with higher overall ratings: Cochrane origin, pharmacological interventions, including exclusively RCTs, citation of methodological and reporting guidelines, protocol, absence of funding and publication after AMSTAR 2 release. Generally, overviews\' authors tended to deviate from the original rating scheme and ascribe higher ratings to SRs compared to the official AMSTAR 2 online tool. Most SRs included in overviews of cardiovascular interventions have critically low or low confidence in their results. Overviews\' authors should be more transparent about the methods used to derive the overall confidence in SRs.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Meta-Analysis
    目的:分析报告它们按照AMSTAR2进行的系统综述(SRs)的方法学质量和特征。
    方法:这是一项横断面荟萃研究。我们搜索了MEDLINE和Embase。我们纳入了报告研究进行的SRs的完整报告,准备好了,或设计符合AMSTAR2。符合条件的SR是从2018年1月1日至2022年5月3日发布的。我们使用AMSTAR2评估了纳入SRs的方法学质量。
    结果:我们共纳入了45条记录。有43个SR和2个SR协议。其中大多数是干预措施的SRs,包括对人类的初步研究。超过一半的人进行了荟萃分析。根据我们对包括SRs的AMSTAR2总体评估,35个SR的置信度极低,7个SR的置信度较低,一个SR很有信心。没有适度自信的SR。
    结论:即使作者在其手稿中指出SR是按照AMSTAR2进行/准备/设计的,也不一定意味着它具有很高甚至中等的置信度。提交时可能需要与AMSTAR2进行自我评估,并由编辑/同行评审员仔细检查。
    OBJECTIVE: To analyze the methodological quality and characteristics of systematic reviews (SRs) that reported they were conducted in line with the AMSTAR 2 (A MeaSurement Tool to Assess Systematic Reviews).
    METHODS: This was a cross-sectional meta-research study. We searched MEDLINE and Embase. We included full reports of SRs reporting the study was conducted, prepared, or designed in line with the AMSTAR 2. Eligible SRs were those published from January 1, 2018, until May 3, 2022. We assessed the methodological quality of the included SRs using AMSTAR 2.
    RESULTS: We included a total of 45 records. There were 43 SRs and 2 SR protocols. Among them, most were SRs of interventions that included primary studies on humans. More than half had a meta-analysis. According to our overall AMSTAR 2 assessments of included SRs, 35 SRs were of critically low confidence, 7 SRs were of low confidence, and one SR was of high confidence. There were no SRs of moderate confidence.
    CONCLUSIONS: Even when authors indicate in their manuscripts that the SR was conducted/prepared/designed in line with the AMSTAR 2, it does not necessarily imply it is of high or even moderate confidence according to AMSTAR 2. A self-assessment with AMSTAR 2 could be required for submission and carefully checked by the editors/peer reviewers.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号